Mammary Tumour Development in BR6 Mice: Hormonal Stimulation by Lee, Audrey E.
568
MAMMARY TUMOUR DEVELOPMENT IN BR6 MICE:
HORMONAL STIMULATION
AUDREY E. LEE
From the Department of Hormone Physiology, Imperial Cancer Research Fund,
Lincoln's Inn Fields, London W.C.2
Received for publication June 3, 1970
SUMMARY.-BR6 female mice treated with a mixture of hormones, developed
mammary tumours earlier than untreated virgin animals. Implantation of
ectopic pituitaries also increased tumour incidence and reduced the age at which
tumours first appeared. This effect was obtained even inthe absence ofovaries.
Neither hormone treatment nor ectopic pituitaries succeeded in producing
tumours as early as they appear in breeding females.
THE BR6 strain of mice resulted from a cross between a C57 Black female and
an RIII male (Foulds, 1947, 1949) and all mice carry a mammary tumour virus
derived from the latter. Mammary tumour incidence in breeding females is 94%
and most tumours first appear during a pregnancy at about 26 weeks of age
(Mundy and Williams, 1961). These tumours are at first pregnancy-dependent,
though later they may grow independently. In virgin mice the tumour incidence
is 48% and tumours seldom appear before the mice are 12 months old.
Although it seems that the hormones of early pregnancy may be sufficient to
stimulate the growth ofexisting (but regressed) tumours (Lee, 1970) the hormones
present in later stages of pregnancy are necessary for the development of new
tumours.
In the first group of experiments described here it was hoped to simulate the
effects ofpregnancy by the administration ofhormones. In the second group the
endocrine status of the mouse was permanently altered by the implantation of
isologous pituitaries at sites remote from hypothalamic control. As prolactin
secretion is controlled by prolactin inhibiting factor from the hypothalamus, a
pituitary removed from this control secretes prolactin unchecked (Muhlbock and
Boot, 1959) whilst the host's own pituitary is controlled in the normal way. In
some experiments pituitary implantation was combined with exogenous hormones,
or with ovariectomy.
MATERIALS AND TECHNIQUES
Mice
Breeding mice were housed 1 pair to a box and left together all the time so that
post partum mating could take place. They were allowed to suckle their litters,
which were weaned at 1 month. Virgin females were housed eight to a box. All
mice had free access to water and Diet GR25 (Dixon: Ware).
Control groups were made up oflitter mates ofthe animals inthe treatedgroups.
Mice which did not develop tumours were kept until they died. Tumours were
measured with calipers twice a week, and the product of two diameters recorded.HORMONES AND MAMMARY TUMOURS IN MICE
Operations
Pituitary grafts were made by removing the pituitaries from adult male mice
(Boot, Muhlbock and Kaligis, 1960) of the same strain and implanting two into
each female host, either under the kidney capsule or subcutaneously into the right
abdominal mammary gland fat pad (under " Avertin " anaesthesia). The latter
method was equally effective and was much the simpler operation. Host mice were
selected by taking vaginal smears for 2 to 3 weeks beforehand and only those mice
showing normal oestrous cycles were used. A graft was considered to have taken
successfully if the mouse subsequently showed mainly dioestrous smears (Boot,
Muhlbock and Kaligis, 1960). Another indication of successful implantation was
that the ectopic pituitaries could often still be seen post mortem and appeared
functional.
Ovariectomy was carried out by dorsal incisions, using ether anaesthesia. At
first mice were ovariectomized before the graft was made, but Boot and Rdpcke
(1966) found that the grafts grew better when the ovaries were present, so subse-
quently the grafts were made first and the ovaries removed about 2 months later.
By performing the operations in this order, it was also possible to judge whether the
graft was established, by examination of vaginal smears.
Injections
The combination of hormones used was based on the regimen found by Nandi
(1958) to be necessary to stimulate lobular-alveolar development ofthe mammary
glands in hypophysectomized ovariectomized and adrenalectomized mice. In
earlier work with BR6 mice, Mundy (unpublished observations) used this combina-
tion but in smaller doses, and with negative results. In the present experiments
the dose ofprolactin was increased to 10 mg. per day but the amounts ofthe other
hormones were kept at the lower levels used by Mundy.
The daily dose contained 1-0 mg. prolactin (Ovine, N.I.H.), 0 5 i.u. adreno-
corticotrophic hormone (Organon) 50 0 ,ug. growth hormone (bovine, N.I.H.),
0 5 lug. oestrone and 0 5 mg. progesterone. In one experiment prolactin was omit-
ted and progesterone increased to 10 mg. per day. The steroids were dissolved in
an aliquot of ethyl alcohol not exceeding 20% of the final volume. Protein
hormones were dissolved or suspended in 09%o (w/v) saline. The two mixtures
were combined so that the resulting suspension contained the required daily dose in
0-1 ml. This was injected subcutaneously using a different site each day in
rotation.
5-Hydroxy-tryptamine creatinine sulphate (5HT) was dissolved in distilled
water. A daily dose of 1P0 mg. was injected subcutaneously.
EXPERIMENTAL
The influence of exogenous hormone stimulation
On regressed pregnancy-dependent mammary tumours. In a preliminary
investigation the mice subjected to hormone stimulation were breeding females
with pregnancy-dependent tumours which had regressed. They were separated
from the males so that they did not become pregnant again. Six mice were
treated with the hormone mixture as described in the Materials and Techniques
section. The duration ofeach course oftreatment was usually about 10 days, but
in one animal it was continued for 4 weeks.
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Three of the mice showed recurrence of tumour growth after one course of
treatment. Two of these tumours regressed when injections were discontinued
and their growth could therefore be regarded as a result of hormone treatment.
The third tumour continued to grow even without further injections. Two mice
showed recurrence of tumour growth after two courses of treatment and both
tumours regressed when treatment stopped. The sixth mouse did not show a
recurrence until after three courses oftreatment and the tumour then continued to
grow independently of hormonal stimulation so was probably not induced by it.
Two breeding mice which had not developed tumours were also treated. These
mice wereboth 18 monthsold; onehadhadfivelittersandtheothersix. Atumour
developed in the first after one course of treatment, and in the other after two
courses, but both tumours continued to grow without further stimulation.
On mammary tumour development in virgin mice.-To simulate pregnancy,
courses of hormone treatment were given approximately once every 2 months to
two groups ofvirgin mice, aged 6 to 12 weeks at the beginning ofthe experiment.
A third group of mice was kept as controls. The combination of hormones used
has been described under Materials and Techniques. Although 5HT alone had not
had any effect on tumour growth in virgin mice (Lee, 1970) it was decided to incor-
porate it in the treatment of one of the groups. The duration of each course of
treatment varied from 9 to 19 days as inclusion of 5HT in the mixture caused
sloughing ofthe skin at the site ofinjection in some mice and treatment was then
stopped in both groups.
TABLE I.-Tumour Incidence in Virgin Mice Treated with Oestrone, Progesterone,
ACTH, Growth Hormone, Prolactin and 5-Hydroxytryptamine (5HT)
Appearance of first tumour
No. with (mean s S.E.)
tumours ,
Treatment total Age in weeks No. oftreatments
Series I . . 4/6 . 94+7t
Hormones + 5HT . 6/6 . 60+7t 6 2+0 9
Hormones without 5HT . 6/6 . 75+11 7*8±1 1
Series II . . 4/7 . 105+4*
Hormones + 5HT (omitting . 6/7 . 81+8* 72±0-6
prolactin but with increased
progesterone)
* PO002 < 0*05.
t P0001 < 0.01.
Table I shows that tumours appeared earlier in the groups given hormones, and
hormones with 5HT (average ages 75 ± 11 and 60 ± 7 weeks respectively), than in
the control group where the average age at tumour appearance was 94 ± 7 weeks.
Moreover two mice in the control group died without mammary tumours aged 104
and 112 weeks. Once they had appeared, all tumours grew independently of
further hormonal stimulation.
As earlier attempts to produce tumours by injections of exogenous hormones
containing smaller doses of prolactin had not been successful, the increased dose
used in these experiments seemed an important factor. Another indication ofthe
importance ofprolactinwasindicatedbytheabilityofpituitaryisograftstopromote
tumours (see next section). If the main effect of prolactin was an indirect one
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through its influence on the corpora lutea, then it should be replaceable by extra
progesterone inthe mixture ofadministered hormones. Agroup ofmice was given
the hormone mixture containing 1.0 mg. progesterone per day (instead of 0.5 mg.)
but without any prolactin. However, as 5HT was also given, this may have
increased endogenous prolactin (Meites, Talwalker and Nicoll, 1960). The dura-
tion ofeach course oftreatment varied from 10 to 19 days. Results are shown in
Table I. Again tumours appeared intreated mice at a significantly lower agethan
in control mice. All tumours grew independently of hormonal stimulation, like
those arising in untreated mice.
The effect ofpituitary isografts on marmmary tumour development in virgin mice
Pituitary grafts alone.-The effect on tumour appearance of continuous pro-
lactin secretion by an ectopic pituitary, is shown in Table II. Virgin mice in
TABLE II.-Tumour Incidence in Mice with Ectopic Pituitary Isografts Placed
in the Kidney (Series I and II) or Subcutaneously (Series III)
Age in weeks when tumour
appeared
No. with ,_A_A
tumours/total Mean ±S.E. Range
Series I . 11/11* . 58±4* 38-84
Series II . 8/10 . 66+4 48-86
Controls . 4/10 . 83+ 10 57-102
Series III . 10/12 . 64±8 28-110
* Significantly different from controls, P 0*02 < 0 -05.
Series I and II received pituitary implants under the kidney capsule when they
were about 10 weeks' old. Virgin mice in Series III received the implants sub-
cutaneously when they were about 8 weeks' old. Implants at both sites were
successful in inducing mammary tumours. Series I showed a significantly higher
tumour incidence and earlier tumour development than the control group of
Series II. The other two treated groups similarly showed higher incidence and
earlier development, though the differences were not significant.
The graft-bearing kidney was removed from six mice (with a total of seven
tumours) ofSeries II. Three tumours continued to grow, one remained the same
size and three regressed. Removal of a kidney from a control mouse with a
tumour did not affect tumour growth.
Pituitarygrafts and hormone treatrment.-To see iftumours couldbe developed at
a still earlier age, courses of hormone treatment were combined with pituitary
implants, placed subcutaneously when the mice were about 11 weeks old. 5HT
was included in the mixture but prolactin was omitted. Other hormones were as
described previously. The courses of treatment were given approximately once
every 2 months, and each lasted 2 to 3 weeks. Tumour incidence is given in
Table III, which also shows the ages of the mice and the number of courses of
hormone treatment they had received when tumours developed. The average age
of the mice when tumours appeared was 58 ± 16 weeks, and this was no earlier
than in mice which had pituitary grafts alone. Nor was it significantly earlier
than in mice which received hormone and 5HT treatment without concurrent
pituitary implants (Table I). However, during the latent period before tumours
appeared, the mice with pituitary implants had received only three courses of
hormone treatment, whereas the mice without implants had received six.
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TABLE III.-Tumour Incidence in Mice with Subcutaneous Pituitary Isografts and
Either Ovariectomized or Treated with Oestrone, Progesterone, ACTH, Grouth
Hormone and 5-Hydroxytryptamine
Age in weeks when tumour
appeared No. ofhormone
No. with , treatments
tumours/total Mean ±S.E. Range (mean S.E.)
Controls 5/11 . 77±5 59-94
Graft + hormones + 5HT . 10/10 58±16 38-84 3±0
Graft + ovariectomy 7/7 . 63±6 49-91
Pituitarygrafts and ovariectomy.-Furtherinvestigation ofwhether the action of
prolactin was directly on the mammary gland, or through its luteotrophic effect
was made by combining pituitary implants with ovariectomy. Mice were aged
about 12 weeks at the time ofthe graft. The results shown in Table III indicate
that tumour development was not reduced by the absence of the ovaries. This
suggests that the ectopic pituitary had a direct influence on the mammary glands.
Local effects ofpituitary grafts.-Direct local action of a pituitary implanted in
the right abdominal mammary gland fat pad was seen in several mice where the
mammary tissue surrounding the graft was very well developed and sometimes
contained a milky secretion.
The location of tumours was also suggestive of a direct effect, as 15 out of 25
tumours (60%) appeared in the right groin adjacent to the pituitary implant. In
control virgin females the incidence of right groin tumours was three out of 26
(12%), and in breeding females 30 out of 195 tumours (15%). The proportion of
right groin tumours in the experimental animals was significantly higher
(P < 0.001) than in either ofthe normal groups.
DISCUSSION
Repeated injection with a mixture of hormones decreased the age at which
non-parous mice developed tumours. However, they still did not appear until the
mice were more than 1 year old. These tumours were hormone-independent, as
they continued to grow even after the hormone injections were stopped. In this
respect they resembled the tumours which appear in some untreated virgin mice,
rather than thepregnancy-dependent tumours arising in younger breeding females.
Thepresence ofan ectopicpituitaryincreasedtumourincidence andreducedthe
ageatwhichtumoursfirstappeared. Thistreatmentproducedhormone-dependent
as well asindependent tumours, as out ofthe seven tumours tested, three regressed.
These three tumours did not appear anyearlierthanthehormone-independent ones.
When pituitary isografts were combined with other procedures the administra-
tion of hormones did not reduce the latent period before tumours appeared
Ovariectomy did not significantly lengthen this period, suggesting that in stimu-
lating the mammary glands of BR6 mice, the direct action of prolactin is more
important than its luteotrophic effect. The direct effect ofprolactin was also seen
inthe position ofthe mammarytumours, as 60% ofthem developed adjacent tothe
ectopic pituitary. Boot (1969) found the effect ofpituitary isografts was systemic
rather than local.
The relationship of the ovaries to ectopic pituitaries in mammary gland and
tumour development, has been investigated in several strains of mice. Mice free
from a mammary tumour agent required the presence ofovaries (Boot and R6pcke,
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1966), or the administration of oestrogen (Muhlbock and Boot, 1967) for tumour
development. However, Hagen and Rawlinson (1964) found males carrying a
mammary tumour agent developed tumours. Strain differences were reported by
Haran-Ghera (1965) in the requirement of ovarian hormones for the production of
preneoplastic lesions. Briggs, Liebelt and Liebelt (1968) observed that mammary
gland response and other systemic effects of pituitary implants differed between
agent-carrying and agent-free mice.
When results from all experiments using hormone injections or pituitary iso-
grafts were combined, tumours developed in 9300 of the mice, compared with a
tumour incidence of4800 in the untreated mice. The tumours in the experimental
mice appeared on average 20 weeks earlier than in their respective control groups.
No one treatment or combination of treatments seemed more effective than the
others. Tumour development therefore can be influenced by several factors, either
acting independently or interacting with each other.
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